Strategic Partnerships Immunovant's alignment with the FDA and upcoming pivotal trials present opportunities for partnership discussions with pharmaceutical companies looking to collaborate on autoimmune disease treatments.
Investment Attraction Recent investments from Rubric Capital Management LP, WCM Investment Management, and other firms indicate market interest and may signal potential for further financial support or partnerships in the biotechnology sector.
Competitor Analysis Monitoring competitors like argenx SE, Federated Hermes, and others can provide insights into market trends, competitive positioning, and areas where Immunovant can differentiate itself to attract new customers or investors.
Market Expansion Immunovant's research in developing treatments for conditions like Graves' disease offers opportunities to explore new markets, secure regulatory approvals, and expand the company's reach to healthcare providers and patients globally.
Tech Integration Leveraging a tech stack that includes Amazon CloudFront, Google Font API, and other tools showcases Immunovant's technological capabilities which can be highlighted to appeal to tech-savvy clients and investors seeking innovative solutions in the biotechnology sector.
54
$10M$50M
322$50M$100M
51$10M$50M
29
50$10M
11Immunovant uses 8 technology products and services including Amazon CloudFront, Microsoft Word, Google Font API, and more. Explore Immunovant's tech stack below.
| Immunovant Email Formats | Percentage |
| First.Last@immunovant.com | 89% |
| Last.First@immunovant.com | 9% |
| First.Middle@immunovant.com | 1% |
| Last@immunovant.com | 1% |
Biotechnology ResearchNew York, United States201-500 Employees
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com. For U.S. residents only.
Company Overview
Media & News
Funding & FinancialsImmunovant has raised a total of $450M of funding over 4 rounds. Their latest funding round was raised on Sep 27, 2023 in the amount of $450M.
Immunovant's revenue is in the range of $50M$100M
Funding & FinancialsImmunovant has raised a total of $450M of funding over 4 rounds. Their latest funding round was raised on Sep 27, 2023 in the amount of $450M.
Immunovant's revenue is in the range of $50M$100M
1-888-653-2347 
support@leadiq.com